Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Strains Under New NDA Review Model; Will Industry Want To Retain It?

Executive Summary

Scheduling mid- and late-cycle meetings complicates reviews for FDA, but the fate of the “Program” probably depends on whether industry feels the extra two months produces better outcomes.

Advertisement

Related Content

Alexander Tells FDA To Create ‘Red Team’ For Regulatory Streamlining
Alexander Tells FDA To Create ‘Red Team’ For Regulatory Streamlining
Senator Tells FDA To Create ‘Red Team’ For Regulatory Streamlining
‘Breakthrough’ Therapies: Information Requests A Sign Of Workload Problem?
PhRMA, BIO’s PDUFA V Application Tracker Could Inform “Course Corrections”
FDA’s Sequestered User Fees From FY 2013 Likely Gone, But FY 2014 Fees Could Be Exempted
First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model
PDUFA V: Review Model Evaluators Will Observe All FDA-Sponsor Meetings
The New User Fee Rules: FDA Sacrifices Timeliness, Tries to Save Predictability

Topics

Advertisement
UsernamePublicRestriction

Register

PS055806

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel